466 related articles for article (PubMed ID: 29602399)
1. Metabolomics and Metabolic Reprogramming in Kidney Cancer.
Weiss RH
Semin Nephrol; 2018 Mar; 38(2):175-182. PubMed ID: 29602399
[TBL] [Abstract][Full Text] [Related]
2. Metabolic reprogramming in clear cell renal cell carcinoma.
Wettersten HI; Aboud OA; Lara PN; Weiss RH
Nat Rev Nephrol; 2017 Jul; 13(7):410-419. PubMed ID: 28480903
[TBL] [Abstract][Full Text] [Related]
3. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma.
Lucarelli G; Loizzo D; Franzin R; Battaglia S; Ferro M; Cantiello F; Castellano G; Bettocchi C; Ditonno P; Battaglia M
Expert Rev Mol Diagn; 2019 May; 19(5):397-407. PubMed ID: 30983433
[TBL] [Abstract][Full Text] [Related]
4. The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma.
Hu SL; Chang A; Perazella MA; Okusa MD; Jaimes EA; Weiss RH;
J Am Soc Nephrol; 2016 Aug; 27(8):2227-37. PubMed ID: 26961346
[TBL] [Abstract][Full Text] [Related]
5. Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis.
Wettersten HI; Hakimi AA; Morin D; Bianchi C; Johnstone ME; Donohoe DR; Trott JF; Aboud OA; Stirdivant S; Neri B; Wolfert R; Stewart B; Perego R; Hsieh JJ; Weiss RH
Cancer Res; 2015 Jun; 75(12):2541-52. PubMed ID: 25952651
[TBL] [Abstract][Full Text] [Related]
6. Targeting Metabolic Pathways in Kidney Cancer: Rationale and Therapeutic Opportunities.
Hoerner CR; Miao SY; Hsieh JJ; Fan AC
Cancer J; 2020; 26(5):407-418. PubMed ID: 32947309
[TBL] [Abstract][Full Text] [Related]
7. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth.
Abu Aboud O; Donohoe D; Bultman S; Fitch M; Riiff T; Hellerstein M; Weiss RH
Am J Physiol Cell Physiol; 2015 Jun; 308(11):C890-8. PubMed ID: 25810260
[TBL] [Abstract][Full Text] [Related]
8. Metabolic reprogramming in renal cancer: Events of a metabolic disease.
Chakraborty S; Balan M; Sabarwal A; Choueiri TK; Pal S
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188559. PubMed ID: 33965513
[TBL] [Abstract][Full Text] [Related]
9. Reprogramming of Metabolism in Kidney Cancer.
Wettersten HI
Semin Nephrol; 2020 Jan; 40(1):2-13. PubMed ID: 32130963
[TBL] [Abstract][Full Text] [Related]
10. HSP60 silencing promotes Warburg-like phenotypes and switches the mitochondrial function from ATP production to biosynthesis in ccRCC cells.
Teng R; Liu Z; Tang H; Zhang W; Chen Y; Xu R; Chen L; Song J; Liu X; Deng H
Redox Biol; 2019 Jun; 24():101218. PubMed ID: 31112866
[TBL] [Abstract][Full Text] [Related]
11. (1)H NMR metabolomics analysis of renal cell carcinoma cells: Effect of VHL inactivation on metabolism.
Cuperlovic-Culf M; Cormier K; Touaibia M; Reyjal J; Robichaud S; Belbraouet M; Turcotte S
Int J Cancer; 2016 May; 138(10):2439-49. PubMed ID: 26620126
[TBL] [Abstract][Full Text] [Related]
12. Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma.
DiNatale RG; Sanchez A; Hakimi AA; Reznik E
Urol Oncol; 2020 Oct; 38(10):755-762. PubMed ID: 31155438
[TBL] [Abstract][Full Text] [Related]
13. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.
Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B
Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
15. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.
Reustle A; Menig LS; Leuthold P; Hofmann U; Stühler V; Schmees C; Becker M; Haag M; Klumpp V; Winter S; Büttner FA; Rausch S; Hennenlotter J; Fend F; Scharpf M; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Clin Transl Med; 2022 Jun; 12(6):e883. PubMed ID: 35678045
[TBL] [Abstract][Full Text] [Related]
16. Metabolic reprogramming of clear cell renal cell carcinoma.
Zhu H; Wang X; Lu S; Ou K
Front Endocrinol (Lausanne); 2023; 14():1195500. PubMed ID: 37347113
[TBL] [Abstract][Full Text] [Related]
17. Pathway analysis of kidney cancer using proteomics and metabolic profiling.
Perroud B; Lee J; Valkova N; Dhirapong A; Lin PY; Fiehn O; Kültz D; Weiss RH
Mol Cancer; 2006 Nov; 5():64. PubMed ID: 17123452
[TBL] [Abstract][Full Text] [Related]
18. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.
Ambrosetti D; Dufies M; Dadone B; Durand M; Borchiellini D; Amiel J; Pouyssegur J; Rioux-Leclercq N; Pages G; Burel-Vandenbos F; Mazure NM
PLoS One; 2018; 13(2):e0193477. PubMed ID: 29481555
[TBL] [Abstract][Full Text] [Related]
19. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
